Track Medicus Pharma Ltd. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Medicus Pharma Ltd. Common Stock MDCX · Stock Open Medicus Pharma Ltd. Common Stock in new tab

1.95 USD
EPS
-119.00
P/B
-13.96
ROE
-7446.11
Beta
0.15
Target Price
203.75 USD
Loading chart...
Key Metrics
Earnings dateMarch 24, 2027
EPS-119.00
Book Value-0.13
Price to Book-13.96
Debt/Equity177.50
% Insiders14.956%
Estimates
Forward P/E-0.08
Forward EPS-24.00
Target Mean Price203.75

DCF valuation

Model fair value for Medicus Pharma Ltd. Common Stock (MDCX)
Result
Sign in to run the valuation for MDCX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus None · mean target 203.75 USD (low 15.00, high 450.00) · as of 9 Nov 2026
Low 15.00
Mean 203.75
High 450.00
Price 1.95
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Medicus Pharma Ltd. Common Stock Logo Medicus Pharma Ltd. Common Stock Analysis (MDCX)

Canada Healthcare Official Website Stock

Is Medicus Pharma Ltd. Common Stock a good investment? Medicus Pharma Ltd. Common Stock (MDCX) is currently trading at 1.95 USD. Market analysts have a consensus price target of 203.75 USD. This suggests a potential upside from current levels.

Earnings Schedule: Medicus Pharma Ltd. Common Stock is expected to release its next earnings report on March 24, 2027. The market consensus estimate for Forward EPS is -24.00.

Investor FAQ

Does Medicus Pharma Ltd. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Medicus Pharma Ltd. Common Stock?

Medicus Pharma Ltd. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 24, 2027. The company currently has a trailing EPS of -119.00.

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.

Exchange Ticker
NASDAQ MDCX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Oct. 12, 2026 1:50
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion